Approved Drugs > FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer
On February 26, 2018, the Food and Drug Administration approved abemaciclib (VERZENIO™, Eli Lilly and Company) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. More Information.
La supervivencia al cáncer de tiroides aumenta un 15%
Hace 12 horas